SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six months ended June 30, 2025, our net loss was $58.9 million, or $1.01 per share, compared to a net loss of $93.2 milli
Related Questions
How will the reduction in net loss year‑over‑year affect OMER's valuation and price target?
What were the primary drivers behind the improved loss performance (e.g., product sales, cost reductions, licensing revenues)?
What is the outlook for cash runway and liquidity after the reported loss, and are there any upcoming financing activities?
Are there any significant R&D milestones or regulatory approvals expected that could accelerate revenue growth?
How does OMER's Q2 2025 earnings per share compare to consensus analyst estimates and to peers in the biotech/pharma space?
What impact will the current loss have on OMER's ability to meet its debt covenants or other financial obligations?
How do OMER's gross margin and operating expense trends compare with previous quarters and industry averages?
What guidance is management providing for the remainder of FY2025, and how does it align with market expectations?
Is there any indication of share buyback activity, dividend changes, or other capital allocation moves in response to the earnings?
How sensitive is OMER's stock to changes in biotech sector sentiment or macroeconomic factors given the recent earnings results?